Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia

Abdella, Saro; Tessema, Masresha; Defar, Atkure; Hussen, Alemayehu; Ejeta, Eshetu; Demoz, Getachew; Tereda, Addisu Birhanu; Dillnessa, Enatenesh; Feleke, Altaye; Amare, Misiker; Nigatu, Frehiwot; Fufa, Yaregal; Refera, Hailu; Aklilu, Ayalew; Kassa, Munir; Kifle, Tsigereda; Whiting, Susan J.; Tollera, Getachew; Abate, Ebba

doi:10.1371/journal.pone.0244269

Cited by 44 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study pointed out that the median time to recovery from SARS COV-2 was 18 days. This is similar to the studies done in Eka Kotebe General Hospital, Ethiopia in which viral clearance lasted for 19 days [ 9 ] and 16 days [ 8 ]. This might be due to relative similarity in care and treatment given for the patients in both study areas.…”

Section: Discussionsupporting

confidence: 89%

“…A study conducted in treatment center found in Ethiopia showed that, the rate of prognosis from COVID-19 for asymptomatic cases was higher when compared to symptomatic COVID-19 cases, and this study reported the average recovery time of 16 days [ 8 ]. Another study conducted in Kotebe treatment center of Ethiopia revealed the media time to recovery from COVID-19 was 19 days and it ranges from 2–71 days [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study

et al. 2021

View full text Add to dashboard Cite

Introduction Despite its alarming spread throughout the world, no effective drug and vaccine is discovered for COVID-19 so far. According to WHO, the recovery time from COVID-19 was estimated to be 2 weeks for patients with mild infection, and 3 to 6 weeks for those with serious illnesses. A studies regarding the median recovery time and its predictors are limited globally and specifically in Ethiopia. Therefore, the aim of this study was to estimate the median time to recovery from COVID-19 and its predictors among COVID-19 cases admitted to WURH, Western Ethiopian. Methods This was a hospital-based retrospective cohort study conducted among 263 adult patients admitted with COVID-19 in WURH treatment center from March 29, 2020 through September 30, 2020. Epidata version 3.2 was used for data entry, and STATA version 14 for analysis. A Cox proportional hazard regression model was fitted to determine factors associated with recovery time. A variable with P-value ≤ 0.25 at bivariable Cox regression analysis were selected for multivariable Cox proportional model. Multivariable Cox regression model with 95% CI and Adjusted Hazard Ratio (AHR) was used to identify a significant predictor of time to recovery from COVID-19 at P-value < 0.05. Results The mean age of patient was 36.8 (SD± 10.68) years. At the end of follow up, two hundred twenty seven observations were developed an event (recovered) with median time to recovery of 18 days with IQR of 10–27 days. The overall incidence rate of recovery was of 4.38 per 100 (95% CI: 3.84, 4.99) person-days observations. Being older age (AHR = 1.59, 95% CI: 1.02, 2.49), presence of fever on admission (AHR = 1.78, 95% CI: 1.21, 2.62), and comorbidity (AHR = 0.56, 95% CI, 0.34, 0.90) were found to have statistically significant association with recovery time. Conclusion and recommendations In general, the median recovery time of patients with COVID-19 cases was long, and factors such as older age group, presence of fever, and comorbidity was an independent predictors of delayed recovery from COVID-19. Intervention to further reduce recovery time at treatment center has to focus on patients those shows symptoms and with comorbidities.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As the body of literature concerning the coronavirus disease 2019 (COVID-19) expands, the pathophysiology and clinical manifestations of acute COVID-19 have become relatively common knowledge. Recovery times from COVID-19 drastically differ between patients and are highly dependent on the presence or absence of various risk factors that contribute to disease severity, such as age, body mass index, and underlying comorbidities ( 1 , 2 , 3 ). Although the clinical hallmarks are well-described, many symptoms are known to carry over into the recovery period, even after the acute phase has subsided.…”

Section: Introductionmentioning

confidence: 99%

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

Miwa

Nakajima

Kaszynski

et al. 2021

Respiratory Investigation

View full text Add to dashboard Cite

Background The long-term repercussions of critical COVID-19 on pulmonary function and imaging studies remains unexplored. In this study, we investigated the pulmonary function and computed tomography (CT) findings of critical COVID-19 patients approximately 100 days after symptom onset. Methods We retrospectively extracted data on critical COVID-19 patients who received invasive mechanical ventilation during hospitalization from April to December 2020 and evaluated their pulmonary function, residual respiratory symptoms, and radiographic abnormalities on CT. Results We extracted 17 patients whose median age was 63 (interquartile range [IQR], 59–67) years. The median lengths of hospitalization and mechanical ventilation were 23 (IQR, 18–38) and 9 (IQR, 6–13) days, respectively. At 100 days after symptom onset, the following pulmonary function abnormalities were noted in 8 (47%) patients: a diffusion capacity of the lung for carbon monoxide (%DL CO ) of <80% for 6 patients (35%); a percent vital capacity (%VC) of <80% for 4 patients (24%); and a percent forced expiratory volume (FEV 1 %) of <70%for 1 patient (6%) who also presented with %DL CO and %VC abnormalities. Twelve (71%) patients reported residual respiratory symptoms and 16 (94%) showed abnormalities on CT. Conclusions Over 90% of the critical COVID-19 patients who underwent invasive mechanical ventilation continued presenting with abnormal imaging studies and 47% of the patients presented with abnormal pulmonary function 100 days after symptom onset. The extent of the residual CT findings might be associated with the degree of abnormal pulmonary function in critical COVID-19 survivors.

show abstract

“…9 Abrahim et al, showed in their study that those participants without comorbidities recovered more quickly than those with at least one comorbidity. 10 Trump et al, in their study reported hypertension as one of the factors which causes delay of viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. 11…”

Section: Comorbiditiesmentioning

confidence: 97%

To study duration of viral clearance in COVID 19 patients: A Prospective study from Bangalore, India

2021

View full text Add to dashboard Cite

Background: COVID-19 infection, which first reported as a cluster of pneumonia from Wuhan, China, in December 2019, has rapidly emerged as a global pandemic. During the early course of the pandemic. The duration of infectious virus replication is an important factor for clinicians. There is a significant correlation between the duration of SARS-CoV-2 virus clearance and the prognosis of COVID-19. Aims and Objective: To study Duration of viral clearance in COVID 19 patients, admitted in an Indian setting. Materials and Methods: The prospective single-center study considered adults patients of both the gender, diagnosed with COVID-19 infection by RT-PCR technique. Necessary demographic and clinical data were collected and selected subjects were followed-up until discharge or death. Based on the number of days required for viral clearance, the subjects were classified as: group 1: ≤ 14 days, group 2: 15-28 days, and group 3:>28 days. Results: The study included 536 patients it was found that mean duration required for viral clearance was around 8.98±3.54. Mean ages noted for group1, 2 and 3(based on viral clearance) were 37.57±13.65 years, 37.12±13.73 years and 49.50±23.56 years respectively. There was a significant difference between mean age of group 1 and 2, as well as group 1 and 3. Moreover, the distribution of patients across different age group was found to be statistically significant (P<0.05). Significant difference was noted between three groups with respect to the comorbidity status (P<0.0001). The COVID-related symptoms dyspnea and cough were more prominent in group 3 (P<0.05). TLC which is statistically significant (p<0.05), lower the TLC more the duration of viral clearance and more the duration of hospital stay. Conclusion: The mean days of viral clearance noted in COVID subjects is around 8.98±3.54 days. There was a significant difference between mean age of group 1 and 2, as well as group 1 and 3. However, there is no statistically significant correlation between duration of hospital stay and inflammatory markers except TLC which is statistically significant (p<0.05), lower the TLC more the duration of viral clearance and more the duration of hospital stay.

show abstract

Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia

Cited by 44 publications

References 27 publications

Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study

Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

To study duration of viral clearance in COVID 19 patients: A Prospective study from Bangalore, India

Contact Info

Product

Resources

About